⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 18, 2018Clinical Cancer Research

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

View Full Paper

Ask AI

Bookmark

Share

Abstract

Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline BRCA mutation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Turner et al. (2018) studied this question.

synapsesocial.com/papers/69d9b4655e5bcb4e3b837b2f https://doi.org/10.1158/1078-0432.ccr-18-1891

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairOriginal Research · 2008 · 859 citations
2The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsOriginal Research · 2011 · 870 citations
3The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapyLate-Phase Clinical Trial · 2011 · 91 citations
4Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic CancersEarly-Phase Clinical Trial · 2017 · 391 citations
5Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerCohort Study · 2016 · 163 citations